Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 628 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Inspiring the next generation of cancer researchers November 16, 2021 Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... September 20, 2024 Female Representation at the Top of the Oncology Field Has Hit... October 20, 2021 Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... January 17, 2023 Load more HOT NEWS Study Reinforces Treatment Idea for Cancer with Microsatellite Instability ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with...
